tiprankstipranks
Trending News
More News >

Novartis announces Coartem Baby approved by Swissmedic

Novartis (NVS) announced Coartem Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. “The new treatment, also known as Riamet Baby in some countries, was developed in collaboration with Medicines for Malaria Venture to treat the potentially deadly mosquito-borne disease. Eight African countries also participated in the assessment and are now expected to issue rapid approvals under the Swiss agency’s Marketing Authorization for Global Health Products procedure. Novartis plans to introduce the infant-friendly treatment on a largely not-for-profit basis to increase access in areas where malaria is endemic,” the company stated.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1